As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare equipment and supplies industry, including Lantheus (NASDAQ: LNTH) and its peers.

The healthcare equipment and supplies sector thrives on innovation in medical devices and consumables, the latter providing recurring revenue. Future growth is buoyed by an aging population with increasing chronic diseases and a shift towards minimally-invasive surgery. Advancements in materials science and AI-driven diagnostics also offer significant opportunities. Key headwinds remain, including pricing pressure from cost-conscious healthcare providers, evolving regulations, and potential supply chain disruptions.

The 36 healthcare equipment and supplies stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 2% while next quarter’s revenue guidance was 1.7% below.

In light of this news, share prices of the companies have held steady as they are up 4.2% on average since the latest earnings results.

Lantheus (NASDAQ: LNTH)

Pioneering the "Find, Fight and Follow" approach to disease management, Lantheus Holdings (NASDAQGM:LNTH) develops and commercializes radiopharmaceuticals and other imaging agents that help healthcare professionals detect, diagnose, and treat diseases.

Lantheus reported revenues of $388.2 million, up 2.7% year on year. This print exceeded analysts’ expectations by 7.8%. Overall, it was a stunning quarter for the company with a beat of analysts’ EPS estimates.

Lantheus pulled off the biggest analyst estimate beat in the group. The results were likely priced in, however, and the stock is flat since reporting. It currently trades at $100.92.

Is now the time to buy Lantheus? Access our full analysis of the earnings results here, it’s free.

Best Q2: Baxter (NYSE: BAX)

With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE: BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.

Baxter reported revenues of $2.96 billion, up 5.3% year on year, outperforming analysts’ expectations by 6%. The business had an incredible quarter with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

The market seems happy with the results as the stock is up 7.2% since reporting. It currently trades at $26.56.

Is now the time to buy Baxter? Access our full analysis of the earnings results here, it’s free.

Weakest Q2: LeMaitre (NASDAQ: LMAT)

Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions.

LeMaitre reported revenues of $70.38 million, up 9.6% year on year, falling short of analysts’ expectations by 1.7%. It was a disappointing quarter as it posted a significant miss of analysts’ EPS guidance for next quarter estimates.

LeMaitre delivered the weakest performance against analyst estimates and weakest guidance update of the whole group. As expected, the stock is down 21.3% since the results and currently trades at $83.25.

Read our full analysis of LeMaitre’s results here.

Teleflex (NYSE: TFX)

With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE: TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide.

Teleflex reported revenues of $570.3 million, up 28.9% year on year. This number topped analysts’ expectations by 2%. Overall, it was an exceptional quarter as it also recorded a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

The stock is down 1.5% since reporting and currently trades at $134.76.

Read our full, actionable report on Teleflex here, it’s free.

Inspire Medical Systems (NYSE: INSP)

Offering an alternative for the millions who struggle with traditional CPAP machines, Inspire Medical Systems (NYSE: INSP) develops and sells an implantable neurostimulation device that treats obstructive sleep apnea by stimulating nerves to keep airways open during sleep.

Inspire Medical Systems reported revenues of $200.6 million, down 7.6% year on year. This result surpassed analysts’ expectations by 3%. It was an exceptional quarter as it also produced a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.

Inspire Medical Systems had the slowest revenue growth among its peers. The stock is up 18.3% since reporting and currently trades at $61.75.

Read our full, actionable report on Inspire Medical Systems here, it’s free.

Market Update

Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.

Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.

By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.